Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Black Lung Disease Companies

Black lung disease, also known as coal workers' pneumoconiosis (CWP), is a lung disease caused by the inhalation of coal dust. Companies associated with black lung disease may be involved in various aspects, including mining operations, health and safety initiatives, medical diagnostics, and treatment.

Black Lung Disease Key Companies Latest Black Lung Disease Companies Update

November 2023: In India, Lupin Limited, a pharmaceutical giant, introduced Vilfuro-G, the first fixed-dose triple combination medication (FDC) in the world, for the treatment of chronic obstructive pulmonary disease (COPD). This significant step comes after the dry powder inhaler (DPI) product received clearance from the Drug Controller General of India. If you suffer from moderate to severe chronic obstructive pulmonary disease (COPD), you need a long-term solution. Lupin Vilfuro-G is the only FDC that combines all three medications. The medicine will be offered in a fixed-dose single-strength form, and the suggested dosage is once day. Beyond 37 million people in India are battling chronic obstructive pulmonary disease. It is one of the top causes of disability and mortality in the country.

July 2023: Boehringer Ingelheim has announced that their supplemental New Drug Application (sNDA) for OFEV (nintedanib) approved by the U.S. Food and Drug Administration (FDA). OFEV is being studied as a possible treatment for fibrosing interstitial lung disease (ILD) in children and adolescents aged 6 to 17. Childhood interstitial lung disorders can be a heavy burden on patients and their families due to the lengthy and complex diagnostic process and the lack of authorized treatments. If given the green light, OFEV would revolutionize the treatment landscape for fibrosing interstitial lung disease in children and teenagers (those between the ages of 6 and 17). The sNDA is derived on the findings of the InPedILD phase III study, which administered OFEV to children and adolescents (6–17 years old) with clinically significant fibrosing ILD. The trial assessed the safety, dose-exposure, and efficacy of OFEV in addition to standard of treatment.List of Black Lung Disease Key companies in the market

Boehringer Ingelheim International GmbH (Germany)

GlaxoSmithKline plc (U.K)

Novartis AG (Switzerland)

Teva Pharmaceutical Industries Ltd. (Israel)

AstraZeneca (U.K)

Koninklijke Philips N.V. (The Netherlands)

GENERAL ELECTRIC (U.S.)

Siemens AG (Germany)

TOSHIBA CORPORATION (Japan)

Medtronic (U.S.)

Black Lung Disease Market Highlights:

Black Lung Disease Market Size

Black Lung Disease Market Trends

Black Lung Disease Market Analysis

Black Lung Disease Market Share

Black Lung Disease Market Highlights:

Black Lung Disease Market Trends

Black Lung Disease Market Analysis

Black Lung Disease Market Share

Black Lung Disease Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.